Cargando…
Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011–2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome
Sickle Cell Disease (SCD) is the most common monogenic disorder globally but qualifies as a rare disease in Germany. In 2012, the German Society for Paediatric Oncology and Haematology (GPOH) mandated a consortium of five university hospitals to develop a disease management program for patients with...
Autores principales: | Kunz, Joachim B., Schlotmann, Andreas, Daubenbüchel, Andrea, Lobitz, Stephan, Jarisch, Andrea, Grosse, Regine, Cario, Holger, Oevermann, Lena, Hakimeh, Dani, Tagliaferri, Laura, Kulozik, Andreas E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509263/ https://www.ncbi.nlm.nih.gov/pubmed/34640578 http://dx.doi.org/10.3390/jcm10194543 |
Ejemplares similares
-
Introduction of Universal Newborn Screening for Sickle Cell Disease in Germany—A Brief Narrative Review
por: Lobitz, Stephan, et al.
Publicado: (2021) -
Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea
por: Allard, Pierre, et al.
Publicado: (2021) -
5613004 NEWBORN SCREENING FOR SICKLE CELL DISEASE IN GERMANY - THE FIRST YEAR
por: Lobitz, S., et al.
Publicado: (2023) -
P1480: SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/Β0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY
por: Allard, P., et al.
Publicado: (2022) -
Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
por: Alashkar, Ferras, et al.
Publicado: (2022)